One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings:The Gulf SAFE registry and Darlington AF registry by Li, Y.-G. et al.
 
  
 
Aalborg Universitet
One-year risks of stroke and mortality in patients with atrial fibrillation from different
clinical settings
The Gulf SAFE registry and Darlington AF registry
Li, Y.-G.; Miyazawa, K.; Wolff, A.; Zubaid, M.; Alsheikh-Ali, A.A.; Sulaiman, K.; Lip, G.Y.H.
Published in:
International Journal of Cardiology
DOI (link to publication from Publisher):
10.1016/j.ijcard.2018.08.091
Creative Commons License
CC BY-NC-ND 4.0
Publication date:
2019
Document Version
Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Li, Y-G., Miyazawa, K., Wolff, A., Zubaid, M., Alsheikh-Ali, A. A., Sulaiman, K., & Lip, G. Y. H. (2019). One-year
risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE
registry and Darlington AF registry. International Journal of Cardiology, 274, 158-162.
https://doi.org/10.1016/j.ijcard.2018.08.091
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Accepted Manuscript
One-year risks of stroke and death in patients with atrial
fibrillation from different clinical settings: The Gulf SAFE
registry and Darlington AF registry
Yan-Guang Li, Kazuo Miyazawa, Andreas Wolff, Mohammad
Zubaid, Alawi A. Alsheikh-Ali, Kadhim Sulaiman, Gregory Y.H.
Lip
PII: S0167-5273(18)34355-9
DOI: doi:10.1016/j.ijcard.2018.08.091
Reference: IJCA 26907
To appear in: International Journal of Cardiology
Received date: 6 July 2018
Revised date: 15 August 2018
Accepted date: 29 August 2018
Please cite this article as: Yan-Guang Li, Kazuo Miyazawa, Andreas Wolff, Mohammad
Zubaid, Alawi A. Alsheikh-Ali, Kadhim Sulaiman, Gregory Y.H. Lip , One-year risks of
stroke and death in patients with atrial fibrillation from different clinical settings: The Gulf
SAFE registry and Darlington AF registry. Ijca (2018), doi:10.1016/j.ijcard.2018.08.091
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
1 
One-year risks of stroke and death in patients with atrial fibrillation from different 
clinical settings: The Gulf SAFE Registry and Darlington AF Registry 
 
Yan-Guang Li, PhD (1,2), Kazuo Miyazawa, MD (1), Andreas Wolff, MD (3), Mohammad 
Zubaid, MD (4), Alawi A. Alsheikh-Ali, MD (5), Kadhim Sulaiman, MD (6), Gregory Y.H. 
Lip, MD (1,7) 
 
(1) Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United 
Kingdom; (2) Department of Cardiology, Chinese PLA Medical School, Beijing, China; (3) 
Division of Family Practice, Chilliwack General Hospital, Chilliwack, British Columbia, 
Canada; (4) Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait, 
Kuwait; (5) College of Medicine, Mohammed Bin Rashid University of Medicine and Health 
Sciences, Dubai, United Arab Emirates; (6) National Heart Center, Royal Hospital, Muscat, 
Oman; (7) Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg 
University, Aalborg, Denmark. 
 
Corresponding Author 
Professor Gregory Y.H. Lip 
Institute of Cardiovascular Sciences,  
University of Birmingham, Birmingham, England, United Kingdom 
Tel: +44 121 5075080; Fax: +44 121 507 5503; Email: g.y.h.lip@bham.ac.uk 
 
  
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
2 
Declarations of interest 
None directly related to this paper. GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, 
Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo.  Speaker for 
Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are 
directly received personally. 
Other authors: None declared. 
 
Keywords: Atrial fibrillation, Stroke prevention, Anticoagulation, Stroke and Mortality, 
Clinical setting 
 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
3 
ABSTRACT 
Background: AF patients from different clinical settings may have varying outcomes. We 
aimed to provide patient-level comparisons using two cohorts of patients with AF from 
different settings.  
Methods: The clinical characteristics, prescription of OAC, one-year risks of stroke and 
mortality were compared between patients with AF included into the Darlington AF registry 
(general practice-based cohort from the United Kingdom, n=2258) and the Gulf SAFE 
(Survey of atrial fibrillation events) registry (emergency room-based cohort from the Gulf 
countries, n=1740). 
Results: Patients from the Gulf SAFE registry were younger, had high prevalence of diabetes, 
vascular disease, heart failure. Patients from the Darlington registry had higher prevalence of 
hypertension, previous thromboembolism event, and higher mean stroke risk. OAC use was 
<60% in high stroke risk patients in both registries. On multivariate analyses, patients from 
Gulf SAFE were independently associated with higher risks of stroke (odds ratio, 2.18 [1.47-
3.23]) and mortality (odds ratio, 1.67 [1.31-2.14]), especially in those with high CHA2DS2-
VASc score (≥2 in males, ≥3 in females) (Darlington vs. Gulf SAFE: 3.51% vs. 5.63 for 
stroke; 11.4% vs. 16.8% for mortality) 
Conclusions: Differences regarding AF patients profile, OAC use and outcomes exist in 
varying clinical settings as reflected by registries from different origins. Tailored AF 
management strategy are needed to fit in different clinical settings. 
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Introduction 
Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide, conferring an increased 
risk of ischemic stroke, systemic embolism (SE), heart failure (HF) and mortality
1, 2
. During 
the past decades, the prevalence of AF has increased significantly because of increasingly 
prevalent contributing factors, including an ageing population, hypertension, diabetes 
mellitus (DM), coronary artery disease (CAD) and HF
3
.  Nevertheless, more limited data on 
AF epidemiology are available from the Middle East (ME), when compared to Western 
countries and Asia
4-6
. 
 
Management of AF requires a holistic and integrated procedure, to Avoid stroke, achieve 
Better symptom management and reduce Cardiovascular and comorbidity (the ABC 
pathway)
7
. AF-related ischemic stroke is one of the most devastating outcomes for AF, which 
can be reduced by oral anticoagulation (OAC) 
8, 9
.  
 
Nevertheless, the prescription rates of OAC and the quality of anticoagulation control varies 
between different geographical areas
10
, which may have implications for outcomes among 
AF patients
11-13
. There is also the perception that outcomes differ by region, ethnicity and 
healthcare provider, even amongst patients with AF.  Hence, evaluating AF epidemiology 
and outcomes between different populations may help us understand the global scenario of 
this common arrhythmia. For example, differences in OAC prescription rates and related 
outcomes among AF patients from the United Kingdom (UK) and the Middle East (ME) have 
never been previously reported. 
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In this study, we aimed to provide patient level comparisons of clinical characteristics, OAC 
use, and one-year risks of stroke and mortality amongst two diverse cohorts of patients with 
AF.  
 
Materials and Methods 
Individual data from two registries were used in this study, including the Darlington AF 
Registry from UK and the Gulf SAFE (Gulf Survey of Atrial Fibrillation Events) Registry 
from ME. Details of both registries have been published
14, 15
.   
 
In brief, the study population of the Darlington Registry was derived from 11 general 
practices serving the town of Darlington, County Durham, UK. All patients with known vital 
status in March 2013 were eligible for inclusion. Majority of the AF patients in the 
Darlington Registry were Caucasian (over 96%)
16
. Data collection of this study was 
performed with GRASP-AF (Guidance on Risk Assessment and Stroke Prevention in Atrial 
Fibrillation) audit tool, which can interrogate primary care database with a pre-defined set of 
search criteria. Information regarding demographic profile, AF diagnosis, comorbidities, 
treatment, and outcomes were collected. All events during 12 months of follow-up were 
manually reviewed and confirmed by imaging and/or stroke physician opinion. Details about 
antithrombotic therapy (ATT), OAC were identified through database audit. Patients were 
classified as using anticoagulants or antiplatelet agents if a prescription was issued 
within the last 6 months of the data collection. 
 
The Gulf SAFE study was a prospective, multinational, observational registry of patients 
visiting the emergency room with AF with a 12-month of follow-up. Detailed methodology 
was previously described
15
. Patients were recruited between October 2009 and June 2010 
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from emergency room of 23 hospitals in six Gulf countries from ME, including Bahrain, 
Kuwait, Qatar, Oman, Yemen, and United Arab Emirates. Data was collected by standardized 
case report form and entered online. Aspects regarding the data included patient 
demographics, medical history, and outcomes. ATT and OAC prescription were also 
identified at discharge which was also the start of follow-up. For patients on Vitamin K 
antagonists who had at least three INR checks, the time in therapeutic range (TiTR) 
was calculated using the well accepted Rosendaal method
17
. 
 
After the exclusion of patients who died within 30 days after recruitment (n=137) and severe 
mitral stenosis (n=167), a total of 3998 patients with AF entered the final analysis, with 2258 
from the Darlington and 1740 from the Gulf SAFE Registry (Supplementary Figure S1). 
 
Definitions 
Individual risks of stroke were assessed using the CHA2DS2-VASc score. The CHA2DS2-
VASc score was calculated based on patients’ risk profile at recruitment. For patients 
from the Gulf SAFE registry, during which time the CHA2DS2-VASc score was in its 
initial period, this score was retrospectively calculated based on information from 
detailed patient records. Low-risk was defined as the CHA2DS2-VASc score of 0 in males 
and 1 in females, medium-risk as 1 in males and 2 in females, and high-risk as ≥2 in males or 
≥3 in females. The CHADS2 (congestive HF, hypertension, age ≥75, DM, stroke/SE/TIA 
[doubled]) score of each patient was also calculated. ATT was defined as prescription of 
OAC (warfarin or non-vitamin K antagonist anticoagulant [NOAC]) or antiplatelets drugs 
(aspirin or clopidogrel). Major outcomes recorded included stroke events and all-cause 
mortality during one-year follow-up. Both ischemic stroke and transient ischemic attack (TIA) 
were identified as stroke events.  
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Statistical analysis 
Descriptive analyses were used in this study. Following testing for normality, continuous 
variables in normal distribution were expressed as mean ± standard deviation (SD), or median 
± interquartile range (IQR) for non-parametric distributions. Categorical variables were 
expressed as observed number of patients and percentages. Comparison between continuous 
variables were analysed using Student’s T test or Mann-Whitney U test, as appropriate. 
Difference between categorical variables were analysed using Pearson chi-square test.  
 
Multivariable logistic regression analysis was used for testing independent risk factors for 
one-year outcome. The performance of the CHA2DS2-VASc score for predicting risk of 
stroke and mortality was analysed by area under curve (AUC). Bootstrap procedure with 
1000 replicates was also used for validating the performance of the CHA2DS2-VASc 
score in the combined population, considering the differences among the two cohorts. 
All tests were two-tailed. A p value <0.05 was considered as statistically significant. 
Analyses were performed using SPSS Statistics, version 23.0 (IBM, SPSS Inc) and STATA 
Software, version 14.0 (Stata Corp, College Station, TX). 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
8 
Results 
 
Baseline characteristics of the two populations are summarised in Table 1. Patients from 
Darlington were older and had higher prevalence of hypertension, previous stroke and TIA, 
with higher CHADS2 and CHA2DS2-VASc scores. Patients from Gulf SAFE countries had 
higher prevalence of DM, vascular disease and HF. The prescription rate of antiplatelet 
agents was higher in the patients from Gulf SAFE, as well as the rate of dual antithrombotic 
therapy, i.e., OAC plus antiplatelet drug. A higher percentage of AF patients from Darlington 
were categorised as high-risk (Supplementary Figure S2). 
 
OAC prescription in Darlington and Gulf countries 
ATT use increased with higher stroke risk strata in both populations, from 49.4% to 88.4% in 
Darlington and 85.1% to 93.7% in Gulf SAFE countries (Figure 1). OAC use also increased 
with higher stroke risk strata, from 23.5% to 46.8% in Darlington and 32.0% to 58.4% in 
Gulf countries. In both populations, OAC use in non-low risk categories of the both 
populations were less than 60%. In the high-risk categories, patients from Gulf SAFE 
countries had more use of dual antithrombotic therapy (28.8% vs. 5.2%). In the Gulf SAFE 
registry, for patients on anticoagulation (n=747), a total of 353 patients (47.3%) had at 
least three INR checks, and these had a mean TiTR of 63.5% (SD=37.0). 
 
One-year risks of stroke and mortality  
Patients from Gulf SAFE registry had higher rates of stroke for each risk category (Table 2).  
Stroke rates increased with higher risk strata in patients from Gulf SAFE countries. Mortality 
rates also increased with higher risk strata in both populations (Table 2). Among high-risk 
patients, one-year mortality rates were 11.4% and 16.8% in patients from Darlington and 
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Gulf SAFE countries, respectively. A relatively higher mortality risk was observed in each 
risk category in AF patients from Gulf SAFE registry compared with Darlington registry 
(Table 2). Among patients with high stroke risk, patients on OAC from the Gulf SAFE 
registry had high risk of stroke and mortality. Such difference was not shown in the 
non-OAC patients (see Supplementary Table S1). 
 
Multivariable analysis for stroke and mortality events 
On multivariable analysis, female sex, and previous stroke were independently 
associated with stroke events (see Table 3). Elderly age, female sex, HF and vascular 
disease were independent risk factors for mortality (see Table 3). Patients from Gulf SAFE 
countries had a doubled risk of stroke and a 67% higher risk of mortality compared with 
those from Darlington. OAC significantly reduced the risk of all-cause mortality by 45% in 
the whole study population. 
 
In the multivariable analysis, OAC did not show a significant reduction of stroke events. 
We then performed a baseline comparison between patients with and without OAC. 
Patients with OAC had a significantly higher CHA2DS2-VASc score (3, IQR [2-5] vs. 3, 
IQR [1-4]; p=0.000) and higher percentage of patients with CHA2DS2-VASc score ≥2 
(see Supplementary Table S2).  
 
As demonstrated in the multivariable analysis, OAC was independently associated with 
mortality reduction; however, such reduction was only shown among patients from the 
Darlington registry (OAC vs. No-OAC: 6.2% vs. 12.4%, Darlington; 11.8% vs. 10.9% 
Gulf SAFE). 
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Predicting risks of stroke and mortality 
The CHA2DS2-VASc score was a good predictor for the one-year risk of stroke in non-
anticoagulated patients, with an AUC of 0.71 (95% confidence intervals [CI], 0.65-0.76) in 
the combined population (n=2036) (Supplementary Figure S3), also in UK and ME cohorts 
separately (AUC for Darlington [n=1179] of 0.74 [95% CI, 0.67-0.81]; AUC for Gulf [n=857] 
of 0.70 [95% CI, 0.63-0.77]). The CHA2DS2-VASc score also had good predictive ability for 
one-year mortality, with an AUC of 0.70 (95%CI, 0.68-0.72) in the combined population 
(Supplementary Figure S3), also in UK and ME cohorts separately (AUC for Darlington of 
0.70 [95% CI, 0.67-0.73]; AUC for Gulf of 0.72 [95% CI, 0.68-0.76]). 
 
The performances of the CHA2DS2-VASc score were confirmed by bootstrap procedure in 
the combined population, which gave an AUC of 0.64 (95%CI, 0.58-0.69) for stroke and of 
0.62 (95%CI, 0.60-0.65) for mortality. 
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Discussion 
 
In the present study, we have performed the first patient level comparisons of clinical 
characteristics, OAC use, and one-year risks of stroke and mortality amongst two cohorts of 
patients with AF. We show differences in stroke risk distribution, OAC use and one-year 
risks of stroke and mortality between patients with AF enrolled in the Darlington AF registry 
(UK) and the Gulf SAFE registry (ME).  
 
Our principal findings are as follows: (i) While large percentages of patients with AF would 
be candidates for OAC in both populations, overall OAC use was suboptimal; (ii) High one-
year rates of stroke and mortality were observed in both populations, especially in the high-
risk patient category, but patients from Gulf SAFE registry had higher risk of stroke and 
mortality compared with those from Darlington registry; (iii) Female sex and previous stroke 
were independent factors associated with stroke, while elderly age, female sex, HF and 
vascular disease were independent risk factors for mortality; and (iv) The CHA2DS2-VASc 
score showed good discrimination in predicting one-year risk of stroke in non-anticoagulated 
patients and mortality in the whole study population, as well as in the Darlington and Gulf 
SAFE cohorts separately 
 
As expected (and shown in the present study), the majority of patients with AF are candidates 
for OAC, given that the latter reduces stroke and mortality
9
. In a prior study from Saudi 
Arabia, this percentage was as high as 92%
18
. Wide regional differences in OAC used among 
patients with AF have been reported. The EORP-AF registry (EURObservational Research 
Programme of AF) showed a high OAC use among European countries (84.9%)
19
. Also, the 
GLORIA-AF registry found highest OAC use in Europe (90.1%), followed by Africa/ME 
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(87.4%)
10
. In the present study, there was still an unmet need given that OAC use was 
suboptimal, as is reflected by high one-year stroke and mortality risks. 
 
Our study shows that even in anticoagulated patients, the one-year rate of stroke was still 
high, with 3.0% in Darlington and 5.3% in Gulf countries. This may suggest a suboptimal 
OAC management in these at-risk patients from both populations, given that OAC use was 
mainly vitamin K antagonists (VKA, e.g. warfarin). The effectiveness of the latter is highly 
dependent on the quality of anticoagulation control
20
. In the Gulf SAFE registry, only 47.3% 
(n=353) patients had at least three INR checks across the 12 months of follow-up, and 
the TiTR was suboptimal (mean 63.5%). For the other patients without INR checks and 
corresponding dosage adjustment, the TiTR might be even lower. The suboptimal 
anticoagulation quality may translate to higher stroke and mortality rates in Gulf SAFE 
countries compared to Darlington, or to other differences not accounted for on multivariate 
analysis which did show an independent effect of study cohort (i.e., 2.18-fold higher risk in 
Gulf SAFE, vs. Darlington) on stroke. Unfortunately, we were unable to provide the TiTR 
information in the Darlington registry, which might have provided more details of 
anticoagulation quality in this population. We would speculate that these patients may 
have higher TiTR, considering a good anticoagulation quality control has consistently 
been shown in AF patients from the UK
21, 22
. 
 
In the multivariable analysis, OAC was associated with mortality reduction, which was 
only shown in the Darlington registry, but not in Gulf SAFE registry. A widely used 
active medical surveillance in the UK for anticoagulated patients might be the major 
reason, enabling routine good anticoagulation quality control and management of other 
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comorbidities. Indeed, in another study from UK, among patients with high stroke risk, 
OAC was associated with 11% to 73% reduced mortality
23
. 
 
For a reduced mortality among patients with AF, good OAC use may be not enough 
and management of other comorbidities is equally important. In the EORP-AF registry, 
one-year mortality was high (5.7%), with cardiovascular death being responsible for the 
majority (70%)
24
. In a prospective, multicentre registry in China, the one-year all-cause 
mortality in patients with AF was 14.6%
25
. In the present study, mortality was high in both 
populations, especially among those with high CHA2DS2-VASc score. On multivariate 
analysis there was an independent effect of study cohort (i.e., 1.67-fold higher risk in Gulf 
SAFE, vs. Darlington) on mortality. Reasons for this may include a different health care level 
and relatively high prevalence of comorbidities (DM, HF and vascular disease) in Gulf SAFE 
at baseline.  
 
Indeed, multiple risk factors were associated with the risks of stroke and mortality in patients 
with AF
26
. Also, we confirm the good performance of the CHA2DS2-VASc score in 
predicting stroke and mortality as was demonstrated previously
27-31
. Stroke only accounts for 
10% of the mortality seen in AF; whilst other cardiovascular diseases account for nearly 
70%
32, 33
. Hence, management of other coexisting cardiovascular diseases and risk factors is 
also necessary. To adequately identify at-risk patients may help implement more aggressive 
management strategies in a holistic and integrated manner to ensure a better outcome
7
. 
 
Limitations 
The present study is the first patient level comparisons of two cohorts of patients with AF, 
from the UK and ME. Nevertheless, there are some limitations. We did not consider patients’ 
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preference which could affect the OAC decision
34
. We did not have data on time in 
therapeutic range among patients on vitamin K anticoagulants in the Darlington cohort, and 
data on our two cohorts were collected before the wide use of non-VKA OACs (NOACs). 
Also, we could not report the risks of major bleeding and intracranial haemorrhage, which 
were not recorded. Darlington is one region in UK, while Gulf SAFE is from multiple 
countries and each may have differences in implementation and guideline adherence. The 
two registries were conducted among different healthcare providers, which could be 
another reason for the differences. This study was not able to differentiate which was 
the predominant factor, which needs further investigation.  In addition, the two cohorts 
were collected in slightly different time periods. The Gulf SAFE study was conducted 
between 2010 to 2012, which was 2 to 3 years earlier than the Darlington registry. Over 
time, there might be some improvement, but considering that the Gulf SAFE study 
covers 23 centres from 6 Gulf countries, the improvement over 2-3 years may not be 
profound and thus, should not change the major conclusions of the present study. 
 
Conclusion 
Stroke prevention was generally suboptimal in two patient cohorts from UK and ME, which 
was associated with high one-year risks of stroke and mortality, particularly so amongst 
patients from ME. The higher risks for stroke and mortality in AF patients from ME countries 
(compared to a UK cohort) merits further studies to enable implementation of cardiovascular 
prevention strategies. 
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FIGURE LEGENDS 
 
Figure 1.  Oral anticoagulant use in patients with atrial fibrillation in Darlington and 
Gulf SAFE countries (%) 
APT=antiplatelet therapy; ATT=antithrombotic therapy; OAC=oral anticoagulation 
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Table 1. Baseline characteristics and antithrombotic therapy in patients with AF from 
Darlington and Middle East 
 
Characteristics 
All 
(n=3,998) 
Darlington 
Registry 
(n=2,258) 
Gulf SAFE 
Registry 
(n=1,740) 
P value 
Demographics 
Age, mean ± SD (y) 67.8 ± 16.6 75.6 ± 12.2 57.7 ± 16.0 < 0.001 
Female, No. (%) 1846 (46.2) 1040 (46.1) 806 (46.3) 0.868 
Medical history, No. (%) 
Hypertension 2389 (59.8) 1404 (62.2) 985 (56.6) < 0.001 
Diabetes mellitus 1041 (26.0) 489 (21.7) 552 (31.7) < 0.001 
Vascular disease 945 (23.6) 388 (17.2) 557 (32.0) < 0.001 
Previous stroke or TIA 631 (15.8) 428 (19.0) 203 (11.7) < 0.001 
Heart failure 905 (22.6) 455 (20.2) 450 (25.9) < 0.001 
Thrombotic risk 
CHADS2 score,  
median (IQR) 
2 (1-3) 2 (1-3) 1 (0-2) < 0.001 
CHA2DS2-VASc score, 
median (IQR) 
3 (2-4) 4 (2-5) 2 (1-4) < 0.001 
Antithrombotic therapy, No. (%) 
OAC 1962 (49.1) 1079 (47.8) 883 (50.7) 0.063 
APT 1962 (49.1) 921 (40.8) 1041 (59.8) < 0.001 
OAC plus APT  449 (11.2) 110 (4.9) 339 (19.5) < 0.001 
No ATT 423 (10.6) 368 (16.3) 155 (8.9) < 0.001 
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APT=antiplatelet therapy; ATT=antithrombotic therapy; CHADS2 score=congestive heart 
failure, hypertension, age>75; diabetes mellitus, previous stroke or TIA [doubled]; 
CHA2DS2-VASc score=congestive heart failure, hypertension, age≥75 [doubled], diabetes 
mellitus, previous stroke or TIA [doubled], vascular disease, age 65-74, sex category [female]; 
IQR=inter quartile range; OAC=oral anticoagulant; SD=standard deviation; TIA=transient 
ischemic attack. 
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Table 2. One-year risks of stroke and mortality in Darlington and Gulf SAFE countries 
 
Characteristics 
 Stroke Mortality 
Risk* (95% CI) Relative risk 
(95% CI) 
P value 
Risk* (95% CI) Relative risk 
(95% CI) 
P value 
Darlington Gulf SAFE  Darlington Gulf SAFE  
Low risk 
0.59 
(0.00-1.75) 
2.84 
(1.25-4.44) 
4.95 
(0.64-38.3) 
0.115 
0.59 
(0.00-1.75) 
2.61 
(1.08-4.13) 
4.52 
(0.58-35.3) 
0.091 
Medium risk 
0.00 
(N/A) 
5.25 
(2.81-7.69) 
N/A 0.001 
0.42 
(0.00-1.25) 
5.86 
(3.29-8.44) 
14.7 
(1.95-110.6) 
< 0.001 
High risk 
3.51 
(2.67-4.35) 
5.63 
(4.20-7.07) 
1.64 
(1.14-2.37) 
< 0.001 
11.40 
(9.95-12.9) 
16.80 
(14.5-19.1) 
1.57 
(1.26-1.96) 
0.007 
*per 100 patient-years; CI=confidence interval; N/A=not applicable, because of no events in this patient group.  
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Table 3. Multivariable analysis of risk factors for stroke and death 
 
Characteristics 
Stroke Death 
OR 95% CI p value OR 95% CI p value 
Elderly (≥ 75) 1.40 0.94-2.08 0.097 3.80 2.77-5.22 < 0.001 
Female 1.51 1.08-2.12 0.017 1.31 1.06-1.64 0.015 
Study cohort
*
 2.18 1.47-3.23 < 0.001 1.67 1.31-2.14 < 0.001 
Heart failure 1.27 0.87-1.86 0.213 2.78 2.21-3.50 < 0.001 
Hypertension 0.91 0.63-1.32 0.622 0.90 0.71-1.15 0.413 
Diabetes mellitus 1.14 0.78-1.65 0.505 1.150 0.90-1.46 0.258 
Previous stroke 3.52 2.46-5.03 < 0.001 1.21 0.92-1.58 0.175 
Vascular disease 1.07 0.72-1.59 0.729 1.92 1.51-2.45 < 0.001 
OAC use 1.01 0.72-1.40 0.974 0.55 0.44-0.69 < 0.001 
* Darlington as reference; CI= confidence interval; OAC=oral anticoagulant; OR=odds ratio. 
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Figure 1 
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Highlights: 
 
(i) Patients profiles regarding demographic factors, baseline comorbidities, and evaluated 
stroke risks were different between the two registries derived from different clinical settings;  
(ii) While large percentages of patients with AF would be candidates for OAC in both 
populations, overall OAC use was suboptimal;  
(iii) High one-year rates of stroke and mortality were observed in both populations, especially 
among patients from Gulf SAFE;  
(iv) Female sex and previous stroke were independent factors associated with stroke; while 
elderly age, female sex, HF and vascular disease were independent risk factors for mortality. 
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